Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Praneetha Musty

Rheumatology Smyrna, GA Medical Doctor

NPI 1306191820 CMS profile 2790278

4441 Atlanta Rd Se Ste 315, Smyrna, GA 30080

Open in the dashboard

General payments

$11,486

711 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Praneetha Musty of Smyrna, GA is reported in the CMS Open Payments database as having received $11,486 across 711 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $700 30
2024 General $695 32
2023 General $1,534 91
2022 General $3,298 188
2021 General $2,351 151
2020 General $1,024 74
2019 General $1,885 145

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Praneetha Musty
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Praneetha Musty were reported at $700. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Praneetha Musty Rheumatology median Middle half National median
2019 $1,885 $744 $153–$2,687 $163
2020 $1,024 $462 $98–$2,027 $114
2021 $2,351 $531 $101–$2,153 $132
2022 $3,298 $627 $125–$2,303 $149
2023 $1,534 $741 $145–$2,524 $160
2024 $695 $830 $166–$2,660 $164
2025 $700 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $2,510 161 payments
  2. AbbVie, Inc. $1,271 76 payments
  3. Novartis Pharmaceuticals Corporation $1,055 61 payments
  4. Pfizer Inc. $1,015 78 payments
  5. Janssen Biotech, Inc. $840 51 payments
  6. UCB, Inc. $679 39 payments
  7. GlaxoSmithKline, LLC. $673 36 payments
  8. Genentech USA, Inc. $559 35 payments
  9. Lilly USA, LLC $512 41 payments
  10. E.R. Squibb & Sons, L.L.C. $369 23 payments
  11. Other $2,003 110 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,259 704 payments
  2. Education $227 7 payments
Products named General payments · program years 2019–2025
  1. Enbrel $1,313 81 payments
  2. RINVOQ $980 56 payments
  3. XELJANZ $923 68 payments
  4. COSENTYX $802 43 payments
  5. Otezla $701 46 payments
  6. BENLYSTA $673 36 payments
  7. Cimzia $579 35 payments
  8. TREMFYA $530 26 payments
  9. SIMPONI ARIA $511 38 payments
  10. Actemra $508 32 payments
  11. Other $6,804 460 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

708

Median for Rheumatology: 1,511

Drug cost

$139,134

Median for Rheumatology: $1,139,948

Branded share of claims

28.1%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 18 $124,839
Hydroxychloroquine Sulfate Generic 186 $4,306
Leflunomide Generic 35 $2,562
Mycophenolate Mofetil Generic 16 $2,286
Methotrexate Methotrexate Sodium Brand 181 $2,178
Celecoxib Generic 21 $931
Prednisone Generic 151 $872
Colchicine Generic 12 $553
Gabapentin Generic 11 $215
Folic Acid Generic 11 $139

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$29,808

Of which drugs: $908

Medicare patients

125

Average age 72

Services billed

501

95 women, 30 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 34%
Diabetes 30%
Chronic kidney disease 25%
Ischemic heart disease 22%
COPD 18%
Depression 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 11 11 $900

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
COSENTYX
$133 — —
ORENCIA
$73 — —
OFEV
$69 — —
Cimzia
$54 — —
Actemra
$49 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

711 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record